Scott Mendel
CIK 1515051 · President & CEO · last filed 2026-10-02
Scott Mendel is a President & CEO who has filed 94 SEC Form 4 insider transactions across 5 companies since 2011. The most recent filing shows the insider was granted $15.0K of QTRX on Oct 2, 2026. Across all open-market trades the lifetime net is −$5.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $287.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GNMK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ADDRESS 2
CARLSBAD, CA 92008
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTRX | Director | 28,454 | $2.83 | $80.5K | $0 | 7 | 2026-10-02 |
| QSI | Director | 141,843 | $1.46 | $207.1K | $0 | 4 | 2026-05-20 |
| Akoya Biosciences, Inc. (AKYA) Delisted | Director | 28,500 | $1.29 | $36.8K | $211.9K | 7 | 2024-10-04 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | President & CEO | 0 | $24.04 | $0 | -$4.12M | 65 | 2021-04-22 |
| ACTIVE NETWORK INC (ACTV) Delisted | Chief Financial Officer | 0 | $33.14 | $0 | -$1.60M | 10 | 2013-11-15 |
Recent Filings
94 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-02 | QTRX | Grant (A) | +4,398 | $15.0K | EDGAR |
| 2026-07-09 | QTRX | Exer (M) | +8,073 | $0 | EDGAR |
| 2026-07-02 | QTRX | Grant (A) | +3,456 | $15.0K | EDGAR |
| 2026-05-20 | QSI | Grant (A) | — | $0 | EDGAR |
| 2026-04-07 | QTRX | Grant (A) | +4,310 | $0 | EDGAR |
| 2026-01-06 | QTRX | Grant (A) | +25,316 | $0 | EDGAR |
| 2025-10-03 | QTRX | Grant (A) | +2,084 | $11.5K | EDGAR |
| 2025-07-10 | — | Other (J) | −28,500 | $0 | |
| 2025-07-10 | QTRX | Grant (A) | +28,653 | $0 | EDGAR |
| 2025-05-21 | QSI | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.